One in four children on the autism spectrum in New Zealand are given melatonin to help them sleep, a new study co-authored by a Better Start National Science Challenge researcher has found.
The study’s lead author Associate Professor Laurie McLay says the treatment, which mimics the body’s natural sleep hormone, can make a huge difference for families with children on the autism spectrum.
“We know that sleep problems are really common for children on the autism spectrum, with between 50% and 80% of children affected,” she says.
“A combination of biological, environmental, behavioural and psychological factors contribute towards sleep problems. From a biological perspective, the timing and amount of melatonin produced in children on the spectrum can differ from typically developing children.
“Sleep deprivation impacts significantly on these children and their families, coming in on top of other challenges, so we feel it is important to understand how to better support them to get a good night’s sleep.”
Melatonin has been funded by Pharmac since 2017 for children on the autism spectrum who have persistent, pervasive sleep problems. It has no known significant side effects, making it an attractive option for parents. It is effective and easy to administer compared to many other treatments.
“An effective alternative is behavioural interventions, however these require a lot of effort and time on the part of parents, as well as professional support that is not always available,” Dr McLay says.
An expert on behavioural interventions for sleep problems, Dr McLay worked with children on the autism spectrum and their families before joining the University of Canterbury as a lecturer and researcher. She wanted to understand how popular melatonin was in New Zealand and worked with a team of researchers, including A Better Start National Science Challenge researcher Nick Bowden, a member of the Big Data team which is using prescription data from the Integrated Data Infrastructure (IDI).
The study utilises a method for identifying cohorts of young people with autism in New Zealand, developed by Nick as part of his doctoral studies. Nicksays he is excited that his method is being used beyond his PhD to provide much-needed information related to autism in New Zealand.
The team obtained data for 11,202 children on the autism spectrum aged up to 18 years in New Zealand. While the efficacy of melatonin for sleep problems in children on the autism spectrum is well-known, the rate and patterns of melatonin use in this country was not.
The study, published in Sleep Medicine in March 2021, found that rates of melatonin dispensing were higher among females, school-aged children and those of European ethnicity. Rates were also higher among those with co-occurring mental health conditions, particularly ADHD. No difference was found in rates of melatonin dispensing for different levels of deprivation and urban/rural locations.
Dr McLay is anticipating a second study will be published later this year, looking at the secondary benefits of improving children’s sleep. Further research is planned to explore how melatonin could be used alongside behavioural interventions to further improve sleep for children on the autism spectrum.
The research does not explore the use of melatonin among children who are not on the autism spectrum. Read the paper here
Article courtesy of the University of Canterbury, canterbury.ac.nz
